The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

265 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-16

Study Completion Date

2019-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the value of Orencia in rapidly progressing Rheumatoid Arthritis (RA).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

NCT02600455

Rheumatoid Arthritis

COMPLETED

Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg

NCT02600468

Rheumatoid Arthritis

COMPLETED

Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study

NCT01694693

Rheumatoid Arthritis

WITHDRAWN

Dose Escalation With Remicade® and Orencia®

NCT01141413

Rheumatoid Arthritis

COMPLETED

Predictors of Adherence to Orencia

NCT01136707

Rheumatoid Arthritis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RA patients treated with Abatacept

Treated with Abatacept as a first-line biologic

Non-interventional

Intervention Type OTHER

Non-interventional

RA patients treated with TNFi

Treated with Tumor necrosis factor inhibitor (TNFi) as a first-line biologic

Non-interventional

Intervention Type OTHER

Non-interventional

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-interventional

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age at enrollment
* Confirmed diagnosed with RA
* Initiated first-line treatment with abatacept, adalimumab, etanercept, or infliximab with a record of the start date at the practice site

Exclusion Criteria

* Does not have at least 1 or more poor RA prognostic factor: Evidence of joint erosions, Positive anti-CCP autoantibodies, Positive RF autoantibodies, Increased CRP levels, Increased ESR levels
* Was followed at the site for less than 1 year since biologic treatment initiation
* Patients with autoimmune diseases: Crohn's, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, anal fistula

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No